drugset

drugset / Trial / NCT01775423

A Study of BBI608 in Adult Patients With Advanced Malignancies

NCT01775423 ↗

Phase 1 Completed 87 enrolled Sumitomo Pharma America, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.

Timeline

Start: 2009-03
Primary completion: 2015-08-06
Completion: 2015-08-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Napabucasin	Small molecule	—	—

Indications